Calidi Biotherapeutics Files 8-K: Material Agreement & Equity Sales
Ticker: CLDWW · Form: 8-K · Filed: Nov 15, 2024 · CIK: 1855485
| Field | Detail |
|---|---|
| Company | Calidi Biotherapeutics, Inc. (CLDWW) |
| Form Type | 8-K |
| Filed Date | Nov 15, 2024 |
| Risk Level | medium |
| Pages | 4 |
| Reading Time | 5 min |
| Key Dollar Amounts | $0.0001, $1.69, $7.5 m, $2 |
| Sentiment | neutral |
Sentiment: neutral
Topics: material-agreement, equity-sale, filing
Related Tickers: CLDI
TL;DR
Calidi Biotherapeutics signed a big deal and sold some stock on Nov 14th. 8-K filed.
AI Summary
On November 14, 2024, Calidi Biotherapeutics, Inc. entered into a material definitive agreement. The company also reported on unregistered sales of equity securities and other events. This filing includes financial statements and exhibits.
Why It Matters
This 8-K filing indicates significant corporate activity, including a new material agreement and equity transactions, which could impact the company's financial structure and future operations.
Risk Assessment
Risk Level: medium — The filing details a material definitive agreement and unregistered equity sales, which can introduce financial and operational risks.
Key Players & Entities
- Calidi Biotherapeutics, Inc. (company) — Registrant
- November 14, 2024 (date) — Date of earliest event reported
FAQ
What is the nature of the material definitive agreement entered into by Calidi Biotherapeutics?
The filing indicates the entry into a material definitive agreement but does not provide specific details about its nature in the provided text.
When was the earliest event reported in this 8-K filing?
The earliest event reported in this 8-K filing was on November 14, 2024.
What other types of events are reported in this 8-K filing besides the material agreement?
The filing also reports on unregistered sales of equity securities and other events.
What is the state of incorporation for Calidi Biotherapeutics, Inc.?
Calidi Biotherapeutics, Inc. is incorporated in Delaware.
What is the SEC file number for Calidi Biotherapeutics, Inc.?
The SEC file number for Calidi Biotherapeutics, Inc. is 001-40789.
Filing Stats: 1,269 words · 5 min read · ~4 pages · Grade level 11.1 · Accepted 2024-11-15 17:02:23
Key Financial Figures
- $0.0001 — ch Registered Common stock, par value $0.0001 per share CLDI NYSE American LLC
- $1.69 — e ("Common Stock"), a purchase price of $1.69 per Share. The closing of the offerin
- $7.5 m — ds from the offering were approximately $7.5 million, before deducting placement agent
- $2 — at an exercise price per share equal to $2.1125, which is equal to 125% of the off
Filing Documents
- form8-k.htm (8-K) — 55KB
- ex4-3.htm (EX-4.3) — 109KB
- ex5-1.htm (EX-5.1) — 11KB
- ex10-1.htm (EX-10.1) — 115KB
- ex99-1.htm (EX-99.1) — 12KB
- ex99-2.htm (EX-99.2) — 12KB
- ex99-3.htm (EX-99.3) — 12KB
- ex5-1_001.jpg (GRAPHIC) — 14KB
- ex99-3_001.jpg (GRAPHIC) — 25KB
- 0001493152-24-046330.txt ( ) — 668KB
- cldi-20241114.xsd (EX-101.SCH) — 4KB
- cldi-20241114_def.xml (EX-101.DEF) — 29KB
- cldi-20241114_lab.xml (EX-101.LAB) — 36KB
- cldi-20241114_pre.xml (EX-101.PRE) — 26KB
- form8-k_htm.xml (XML) — 6KB
Financial Statements and Exhibits
Financial Statements and Exhibits. (d) Exhibits. Exhibit No. Description 4.3 Form of Placement Agent Warrant 5.1 Opinion of Sichenzia Ross Ference Carmel LLP 10.1 Form of Placement Agency Agreement 23.1 Consent of Sichenzia Ross Ference Carmel, LLP (contained in Exhibit 5.1) 99.1 Launch Press Release Dated November 13, 2024 99.2 Pricing Press Release dated November 14, 2024 99.3 Closing Press Release dated November 15, 2024 104 Cover Page Interactive Data File (embedded within the Inline XBRL document). -3-
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. CALIDI BIOTHERAPEUTICS, INC. Dated: November 15, 2024 By: /s/ Andrew Jackson Name: Andrew Jackson Title: Chief Financial Officer -4-